Acute lymphoblastic leukemia (ALL) represents around 70% of pediatric leukemia. In high-income countries, the 5-year survival is above 90%, but survival in low- and middle-income countries is inferior ...

New England Journal of Medicine Source Reference: Gupta S, et al "Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children" N Engl J Med 2024; DOI: 10.1056/NEJMoa2411680.

Chemotherapy-free regimens in Philadelphia chromosome–positive acute lymphoblastic leukemia and optimization of combination therapies are among advances from ASH 2023 chosen by Dr Hagop Kantarjian.

2025年合成生物学创新赛第13期《科普专栏》文章来自中国人民解放军海军军医大学 Synth NK团队题为：武装过继：“CAR”山之石，可以攻玉“CAR”山之石,可以攻玉Synth NK武装过继传奇之旅细胞治疗的来时路1.

People with the subtype of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) associated with fusion of MEF2D with other genes show quite poor prognosis. Most patients fail to respond to ...

Because adult patients now more frequently receive pediatric-inspired acute lymphoblastic leukemia (ALL) treatment, their tolerance to such therapy has become an important issue. 1, 2 Depending on the ...

Highlights in acute lymphoblastic leukemia (ALL) from ASH 2024 include significant results for blinatumomab in pediatric ALL, potential use of asciminib, and frontline use of CAR-T cell therapy.

Acute lymphoblastic leukemia has a good outlook or prognosis in children but a poorer outlook in adults. Infant variety of ALL however has a poor prognosis. There are some common factors that ...